These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9517932)

  • 1. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.
    Yamaguchi K; Domon H; Miyazaki S; Tateda K; Ohno A; Ishii K; Matsumoto T; Furuya N
    Antimicrob Agents Chemother; 1998 Mar; 42(3):555-63. PubMed ID: 9517932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem.
    Fukuoka T; Ohya S; Utsui Y; Domon H; Takenouchi T; Koga T; Masuda N; Kawada H; Kakuta M; Kubota M; Ishii C; Ishii C; Sakagawa E; Harasaki T; Hirasawa A; Abe T; Yasuda H; Iwata M; Kuwahara S
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2652-63. PubMed ID: 9420035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
    Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
    Ueda Y; Kanazawa K; Eguchi K; Takemoto K; Eriguchi Y; Sunagawa M
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4185-96. PubMed ID: 16189097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.
    Di Modugno E; Broggio R; Erbetti I; Lowther J
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2742-8. PubMed ID: 9420050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals.
    Fujimoto K; Takemoto K; Hatano K; Nakai T; Terashita S; Matsumoto M; Eriguchi Y; Eguchi K; Shimizudani T; Sato K; Kanazawa K; Sunagawa M; Ueda Y
    Antimicrob Agents Chemother; 2013 Feb; 57(2):697-707. PubMed ID: 23147735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.
    Miyazaki S; Hosoyama T; Furuya N; Ishii Y; Matsumoto T; Ohno A; Tateda K; Yamaguchi K
    Antimicrob Agents Chemother; 2001 Jan; 45(1):203-7. PubMed ID: 11120966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem.
    Asahi Y; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1995 May; 39(5):1030-7. PubMed ID: 7625784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.
    Tsuji M; Ishii Y; Ohno A; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Jan; 42(1):94-9. PubMed ID: 9449267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
    Jones RN; Pfaller MA; Jacobs MR; Appelbaum PC; Fuchs PC
    Diagn Microbiol Infect Dis; 2001; 41(1-2):1-14. PubMed ID: 11687308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice.
    Fukuoka T; Kawada H; Kitayama A; Koga T; Kubota M; Harasaki T; Kamai Y; Ohya S; Yasuda H; Iwata M; Kuwahara S
    Antimicrob Agents Chemother; 1998 Jan; 42(1):23-7. PubMed ID: 9449255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem.
    Sakagawa E; Otsuki M; Oh T; Nishino T
    J Antimicrob Chemother; 1998 Oct; 42(4):427-37. PubMed ID: 9818740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.
    Tanaka M; Hohmura M; Nishi T; Sato K; Hayakawa I
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1260-8. PubMed ID: 9174181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.
    Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G
    J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
    Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.